The opioid epidemic started in the 1990s when pharmaceutical companies convinced doctors that powerful prescription painkillers carried little risk of addiction. That claim was wrong, and the consequences have been staggering: more than half a million Americans have died from opioid overdoses since 1999, with roughly 52,000 opioid-related deaths projected in the 12-month period ending November 2025. What began as a prescribing problem evolved into a crisis involving heroin and then illicit fentanyl, each transition making the epidemic deadlier and harder to control.
A Four-Sentence Letter That Changed Everything
One of the earliest seeds of the crisis was planted in 1980, when two researchers published a brief letter in the New England Journal of Medicine. It was not a study. It was four sentences long, describing outcomes among more than 11,000 hospitalized patients who had received opioid medications under supervised care. The letter noted that addiction among these patients was rare. That narrow observation, made in a controlled hospital setting where nurses administered doses on a schedule, would go on to be cited more than 1,200 times in the medical literature. Over the years, the letter was referenced as though it proved something it never claimed: that opioids were broadly safe for outpatients managing chronic pain on their own at home.
Purdue Pharma and OxyContin
In 1995, the FDA approved Purdue Pharma’s extended-release oxycodone, branded as OxyContin. The drug’s label should have been narrow, restricted to severe pain from conditions like terminal cancer where the benefits clearly outweighed the risks. Instead, the FDA granted a broad indication that allowed Purdue to promote OxyContin for common conditions like low-back pain and fibromyalgia, conditions for which opioids are more likely to harm than help.
Purdue’s sales force then delivered a message that contradicted decades of medical understanding. Doctors who had always known opioids were addictive began hearing from company representatives that addiction was rare and that long-term use was safe and effective. This wasn’t a passive misunderstanding. It was an active marketing campaign backed by enormous financial incentives.
The tactics used across the pharmaceutical industry were aggressive. A U.S. Senate investigation into one manufacturer, Insys Therapeutics, revealed a system built entirely around compensation. Sales representatives earned bonuses tied to high-dosage prescriptions. Managers told reps to “hold the customer accountable” when doctors failed to sustain or increase prescribing, sometimes leveraging personal relationships with physicians to apply pressure. Company executives talked about “owning” a physician, meaning that reps should tightly monitor and control prescribing behavior. Patients were referred to internally as “annuities” for sales reps. As one national sales director wrote in a 2013 email: “What drives us all? COMPENSATION.”
Purdue used similar strategies, including paid speaker programs that positioned sympathetic doctors as educators promoting the drug to their peers. These programs often lacked genuine educational purpose or meaningful safety content.
Pain as a “Fifth Vital Sign”
The pharmaceutical push landed in a medical culture that was already shifting. In 2000, the Joint Commission, the organization that accredits American hospitals, announced new standards for pain management. Hospitals were expected to perform systematic pain assessments using numerical scales, asking every patient to rate their pain from zero to ten. An early implementation example described pain as a “fifth vital sign,” placing it alongside blood pressure, heart rate, temperature, and breathing rate.
The intent was compassionate. Patients’ pain had genuinely been undertreated for years. But tying pain scores to hospital accreditation created pressure to bring those numbers down quickly, and the fastest tool available was opioids. One study found that after a hospital made numerical pain scores mandatory and required acceptable scores before patients could leave the recovery unit, average opioid consumption per patient rose from 40.4 mg to 46.6 mg of morphine equivalents within two years. The Institute for Safe Medication Practices linked this overaggressive approach to pain management with a substantial increase in oversedation and fatal breathing suppression events. Another report found that opioid oversedation incidents more than doubled, rising from 11.0 to 24.5 per 100,000 inpatient hospital days after hospitals implemented numerical pain treatment protocols.
The Joint Commission quietly walked back the “fifth vital sign” language by 2002 and deleted it entirely by 2004, but the cultural shift had already taken hold. Doctors had been trained, incentivized, and pressured from multiple directions to prescribe more opioids, and prescribing rates continued climbing.
Regulators Who Didn’t Act
The FDA had opportunities to course-correct early. Reports of OxyContin abuse surfaced within a few years of its launch. In January 2002, the FDA convened an advisory committee to discuss the risks of opioid analgesics. Committee members acknowledged the problem of abuse but ultimately advised caution in the opposite direction. They warned that restricting opioid access could hurt legitimate patients and “reverse the tremendous progress that has been achieved in the appropriate treatment of pain.” The result was inaction at a moment when the prescribing pipeline was already flooding communities with pills.
The broader regulatory failure was structural. The FDA had not properly enforced its own rules when it approved OxyContin’s broad label in the first place. A narrower indication would have limited Purdue’s marketing to a smaller group of patients with severe, life-limiting pain. Instead, the broad label gave the company legal cover to promote OxyContin for the kinds of everyday pain conditions that affect tens of millions of Americans.
The First Wave: Prescription Opioids
The CDC describes the opioid epidemic as unfolding in three distinct waves. The first began in the 1990s with the surge in opioid prescribing. Overdose deaths involving prescription opioids, including drugs like oxycodone, hydrocodone, and methadone, began rising around 1999 and climbed steadily for over a decade. By the late 2000s, the United States was consuming the vast majority of the world’s opioid supply, and millions of Americans had developed physical dependence on pills that had been prescribed to them by their own doctors.
The Second Wave: Heroin
The second wave began in 2010, driven by an event that was supposed to help. In August of that year, Purdue Pharma pulled the original OxyContin from the market and replaced it with a reformulated version designed to be harder to crush or dissolve for snorting or injection. The abuse-deterrent formula made OxyContin far less appealing to people who had been misusing it. But it did nothing to address their underlying dependence.
Many switched to heroin, which was cheaper and readily available. Research from the National Bureau of Economic Research traced the timeline precisely: opioid consumption stopped rising in August 2010, and heroin deaths began climbing the very next month. The growth in heroin deaths was greatest in areas that had the highest pre-reformulation access to both heroin and prescription opioids. The reformulation did not reduce the combined death toll from heroin and opioids. Each prevented opioid death was effectively replaced by a heroin death. From 2010 through 2014, heroin death rates rose dramatically, roughly quadrupling over that period.
The Third Wave: Illicit Fentanyl
The third and deadliest wave began around 2013, when illegally manufactured fentanyl and its chemical analogs entered the drug supply. Fentanyl is roughly 50 times more potent than heroin by weight, making it extraordinarily profitable for traffickers and extraordinarily dangerous for users. A dose miscalculated by even a fraction of a milligram can be fatal.
Illicit fentanyl has come to dominate the crisis almost entirely. In the most recent provisional data from the CDC, synthetic opioids (predominantly fentanyl) account for about 90.5% of all opioid overdose deaths, roughly 47,100 out of 52,000 total opioid deaths in the 12-month period ending November 2025. The drug supply itself has become the primary danger. People using heroin, counterfeit pills, or even stimulants like cocaine and methamphetamine may unknowingly encounter fentanyl mixed into what they purchased.
Why It Kept Getting Worse
The opioid epidemic wasn’t caused by a single decision or a single company. It was the result of reinforcing failures across every institution that should have provided a check. Pharmaceutical companies marketed aggressively and misrepresented risk. A respected medical journal published a tiny, context-free observation that was inflated into settled science. The FDA approved a broad label it should have narrowed. Hospital accreditation standards pressured doctors to treat pain scores as emergencies. Regulatory bodies that saw early warning signs chose not to restrict access for fear of undertreating pain. And when policymakers finally cracked down on pills, they did so without adequate treatment infrastructure for the millions already dependent, pushing people toward more dangerous street drugs.
Each of these failures fed the next. The result is a crisis that has killed more Americans than any other drug epidemic in the country’s history, one that began with a promise that these drugs were safe and has persisted because the demand they created outlasted every attempt to cut off supply.